Healthcare Business Recap: J&J’s Janssen Gets FDA Okay, AspenBio Gets Dismissal

Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech division has requested FDA approval of Simponi, which is its investigational intravenous formulation for the treatment of adults suffering from moderately to severely active rheumatoid arthritis.

Don’t Miss: Home Builder Stocks: A Look at How They’ve Helped Investors Feel Good Vibrations.

Shares of AspenBio Pharma, Inc. (NASDAQ:APPY) moved up following the Tuesday dismissal by a United States District Court of both class action lawsuits against the firm and certain of its former or current officers and directors, along with the Mark Chipman lawsuit filed against it.

Chief Executive Joe Flatley of Illumina, Inc. (NASDAQ:ILMN) explained to Bloomberg that while the fiscal cliff will impact one third of the firm’s customers, “it’s going to probably be pretty short-lived.” Also, Flatley remarked that Roche (RHHBY.PK) going public in January with its $6.7 billion bid for Illumina prevented the board from properly discussing the offer.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>